Short Interest in Connect Biopharma Holdings Limited (NASDAQ:CNTB) Drops By 42.5%

Connect Biopharma Holdings Limited (NASDAQ:CNTBGet Rating) was the target of a large drop in short interest during the month of May. As of May 15th, there was short interest totalling 183,100 shares, a drop of 42.5% from the April 30th total of 318,400 shares. Based on an average daily volume of 244,800 shares, the days-to-cover ratio is currently 0.7 days.

Several research analysts have weighed in on CNTB shares. Zacks Investment Research cut Connect Biopharma from a “buy” rating to a “hold” rating in a research report on Wednesday, April 6th. Piper Sandler cut Connect Biopharma from an “overweight” rating to a “neutral” rating in a research report on Thursday, May 5th. Finally, SVB Leerink started coverage on Connect Biopharma in a research report on Friday, April 1st. They set a “buy” rating and a $22.00 price objective on the stock.

A number of institutional investors have recently added to or reduced their stakes in the business. Woodline Partners LP bought a new position in Connect Biopharma in the first quarter valued at about $132,000. Vident Investment Advisory LLC bought a new position in Connect Biopharma in the first quarter valued at about $55,000. Invesco Ltd. grew its position in Connect Biopharma by 135.9% in the first quarter. Invesco Ltd. now owns 60,449 shares of the company’s stock valued at $183,000 after acquiring an additional 34,820 shares during the last quarter. Kynam Capital Management LP acquired a new stake in shares of Connect Biopharma during the first quarter valued at about $688,000. Finally, BlackRock Inc. boosted its stake in shares of Connect Biopharma by 4.3% during the first quarter. BlackRock Inc. now owns 2,236,392 shares of the company’s stock valued at $6,755,000 after purchasing an additional 92,632 shares in the last quarter. Hedge funds and other institutional investors own 34.21% of the company’s stock.

Connect Biopharma stock opened at $0.85 on Friday. Connect Biopharma has a 12-month low of $0.56 and a 12-month high of $29.27. The business’s 50-day moving average price is $2.11 and its two-hundred day moving average price is $4.08.

About Connect Biopharma (Get Rating)

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps.

Further Reading

Receive News & Ratings for Connect Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Connect Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.